Juno Therapeutics (JUNO) Prices Upsized Offering at $24, Above Expected Range
Get Alerts JUNO Hot Sheet
Join SI Premium – FREE
Juno Therapeutics (NASDAQ: JUNO) priced its initial public offering of 11,022,917 shares of common stock at a price to the public of $24 per share, above the expected $21-$23 range which was recently raised from $15-$18. The number of shares offered was raised from 9,250,000 shares. Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market today under the symbol "JUNO."
Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any.
Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering. Leerink Partners LLC is acting as a co-manager.
Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Select Medical Holdings (SEM) unit Concentra files confidentially for IPO
- Osisko Development (ODV) Announces Mineral Resource Update for the Trixie Deposit, Tintic Project
- Elicio Therapeutics (ELTX) Announces $6.0 Million Private Placement Financing
Create E-mail Alert Related Categories
Hot IPOs, IPOs, Trader TalkRelated Entities
JPMorgan, Morgan Stanley, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!